Recent Advances in Type 1 Diabetes: Teplizumab (Tzeild ® )

Abstract

Get full access to this article

View all access options for this article.

References

Holt

DeVries

Hess-Fischl

et al. The management of type 1 diabetes in adults. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589-2625.

Lucier

Weinstock

RS.

Type 1 diabetes. In: StatPearls. StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK507713/

Centers for Disease Control and Prevention. National Diabetes statistics report. Last reviewed November 29, 2023. Accessed September 11, 2023. https://www.cdc.gov/diabe-tes/data/statistics-report/index.html

Lawrence

Divers

Isom

et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA. 2021;326(8):717-727.

Mobasseri

Shirmohammadi

Amiri

Vahed

Hos-seini Fard

Ghojazadeh

Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10(2):98-115.

Giwa

Ahmed

Omidian

et al. Current understandings of the pathogenesis of type 1 diabetes: genetics to environment. World J Diabetes. 2020;11(1):13-25.

Keskinen

Korhonen

Kupila

et al. First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia. 2002;45:1639-1648.

Diabetes Prevention Trial - type 1 diabetes study group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. NEJM. 2022;346(22):1685-1691.

Klinke

2nd . Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One. 2008;3(1):e1374. doi:10.1371/journal.pone.0001374

10.

El Sayed

Aleppo

Aroda

et al. American Diabetes Association. Section 2- classification and diagnosis of diabetes. In Standards of Care in Diabetes — 2023. Diabetes Care. 2023;46(suppl 1):S19-S40.

11.

Gregory

Robinson

TIG

Linklater

et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modeling study. Lancet Diabetes Endocrinol. 2022;10:741-760.

12.

Fullerton

Jeitler

Seitz

et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2014(2):CD009122.

13.

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM. 2005;353(25):2643-2653.

14.

Foster

Beck

Miller

et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.

15.

US Food and Drug Administration. FDA news release. FDA approves first drug that can delay onset of type 1 diabetes. Published November 17, 2022. Accessed September 11, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes

16.

Tzield® (teplizumab-mzwv) injection, for intravenous use. Package insert. Accessed September 11, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf

17.

Nourelden

Elshanbary

El-Sherif

et al. Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: a systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets. 2021;21:1895-1904.

18.

Sherry

Hagopian

Ludvigsson

et al. xTeplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378:487-497.

19.

Hagopian

Ferry

Jr Sherry

et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes. 2013;62:3901-3908.

20.

Herold

Bundy

Long

; et al Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. NEJM. 2019;381:603-613.

21.

Sims

Besser

REJ

Dayan

et al. Screenign for type 1 diabtes in the general population: a status report and perspective. Diabetes. 2022;71:610-623.

22.

Mencher

Frank

Fishbein

Diabetic ketoacidosis at onset of type 1 diabetes: rates and risk factors today to 15 years ago. Glob Pediatr Health. 2019;6:2333794X19870394. doi:10.1177/2333794X19870394

23.

Kaiser Family Foundation Health News. Morning Briefing. New diabetes drug to cost $13,850 per vial, more than some estimates. Published November 21, 2022. Accessed September 15, 2023. https://kffhealthnews.org/morning-breakout/new-diabetes-drug-to-cost-13850-per-vial-more-than-some-estimates/

24.

Scheiner

Weiner

Kruger

Pettus

Screening for type 1 diabetes: role of the diabetes care and education specialist. ADCES in Practice. 2022;10:20-25.